Hemogenyx Pharmaceuticals (HEMO)

Sector:

Pharma and Biotech

1.64p
   
  • Change Today:
    -0.030p
  • 52 Week High: 3.96
  • 52 Week Low: 1.17
  • Currency: UK Pounds
  • Shares Issued: 1,341.82m
  • Volume: 5,990,463
  • Market Cap: £22.02m
  • RiskGrade: 340

Silver Falcon admits first takeover talks are at early stage

By Oliver Haill

Date: Wednesday 30 Dec 2015

LONDON (ShareCast) - (ShareCast News) - Responding to media speculation, Silver Falcon, the buy-and-build financial technology company, confirmed it was in the midst of takeover discussions with a possible target.


Silver Falcon, which floated on London's main board in early November, said discussions were at an early stage and dismissed much of the recent press speculation was "factually incorrect and should not be relied upon".

Media reports last week speculated that Silver Falcon was working on a deal valued at roughly £15-20m and likely to occur within days.

The company was set up by merchant banker Geoffrey Dart, a former director of London & Boston, Energy Technique and Hayward Tyler, financier Peter Redmond and the venture capitalist Adrian Beeston, as a "special purpose acquisition company" to acquire businesses in the technology-focused end of the financial services market.

In its after-hours statement on Monday, the company stressed that there was no certainty that any such agreements will be made.

"Whilst the company has had initial discussions with a possible target concerning a possible transaction, all such discussions are at a preliminary stage," it said.

Up 15% on Monday to 4.6p, shares in the company, of which 4.3m were placed at 3p on listing, were more than 50% ahead of their issue price.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HEMO Market Data

Currency UK Pounds
Share Price 1.64p
Change Today -0.030p
% Change -1.80 %
52 Week High 3.96
52 Week Low 1.17
Volume 5,990,463
Shares Issued 1,341.82m
Market Cap £22.02m
RiskGrade 340

HEMO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.51% below the market average48.51% below the market average48.51% below the market average48.51% below the market average48.51% below the market average
69.81% below the sector average69.81% below the sector average69.81% below the sector average69.81% below the sector average69.81% below the sector average
Price Trend
20.69% below the market average20.69% below the market average20.69% below the market average20.69% below the market average20.69% below the market average
47.37% above the sector average47.37% above the sector average47.37% above the sector average47.37% above the sector average47.37% above the sector average
Income Not Available
Growth Not Available

HEMO Dividends

No dividends found

Trades for 19-Apr-2024

Time Volume / Share Price
16:29 5,342 @ 1.64p
16:26 51,212 @ 1.65p
16:21 90,000 @ 1.62p
16:09 14,868 @ 1.62p
16:09 50,000 @ 1.62p

HEMO Key Personnel

CEO Vladislav Sandler Ph.D.

Top of Page